Nvidia's advancements in artificial intelligence are drastically reducing the cost of drug discovery, with a reported 70% cost crash. Pharmaceutical giant Eli Lilly has recognized this potential by investing $1 billion in AI-driven drug discovery efforts. This significant investment highlights the growing confidence in AI's transformative power to accelerate and optimize the development of new medicines, potentially revolutionizing the pharmaceutical industry.